140 related articles for article (PubMed ID: 37995423)
1. Circulating tumor cells as a predictor and prognostic tool for metastatic clear cell renal carcinoma: An immunocytochemistry and genomic analysis.
Tariki MS; Barberan CCG; Torres JA; Ruano APC; Ferreira Costa DJ; Braun AC; da Silva Alves V; de Cássio Zequi S; da Costa WH; Fay AP; Torrezan G; Carraro DM; Domingos Chinen LT
Pathol Res Pract; 2024 Jan; 253():154918. PubMed ID: 37995423
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial.
Basso U; Facchinetti A; Rossi E; Maruzzo M; Conteduca V; Aieta M; Massari F; Fraccon AP; Mucciarini C; Sava T; Santoni M; Pegoraro C; Durante E; Nicodemo M; Perin A; Bearz A; Gatti C; Fiduccia P; Diminutto A; Barile C; De Giorgi U; Zamarchi R; Zagonel V
Oncologist; 2021 Sep; 26(9):740-750. PubMed ID: 34077597
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of circulating tumour cells (CTCs) and CTC white blood cell clusters in patients with renal cell carcinoma.
Guan Y; Xu F; Tian J; Gao K; Wan Z; Wang Y; Gao M; Wang Z; Chong T
BMC Cancer; 2021 Jul; 21(1):826. PubMed ID: 34271857
[TBL] [Abstract][Full Text] [Related]
4. Analogous detection of circulating tumor cells using the AccuCyte
van der Toom EE; Groot VP; Glavaris SA; Gemenetzis G; Chalfin HJ; Wood LD; Wolfgang CL; de la Rosette JJMCH; de Reijke TM; Pienta KJ
Prostate; 2018 Mar; 78(4):300-307. PubMed ID: 29285777
[TBL] [Abstract][Full Text] [Related]
5. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
Zhou J; Dong F; Cui F; Xu R; Tang X
Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two detection systems for circulating tumor cells among patients with renal cell carcinoma.
Bai M; Zou B; Wang Z; Li P; Wang H; Ou Y; Cui K; Bian J; Li S; Xu X
Int Urol Nephrol; 2018 Oct; 50(10):1801-1809. PubMed ID: 30120680
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.
Galardi F; De Luca F; Biagioni C; Migliaccio I; Curigliano G; Minisini AM; Bonechi M; Moretti E; Risi E; McCartney A; Benelli M; Romagnoli D; Cappadona S; Gabellini S; Guarducci C; Conti V; Biganzoli L; Di Leo A; Malorni L
Breast Cancer Res; 2021 Mar; 23(1):38. PubMed ID: 33761970
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer.
Chalfin HJ; Pramparo T; Mortazavi A; Niglio SA; Schonhoft JD; Jendrisak A; Chu YL; Richardson R; Krupa R; Anderson AKL; Wang Y; Dittamore R; Pal SK; Lara PN; Stein MN; Quinn DI; Steinberg SM; Cordes LM; Ley L; Mallek M; Sierra Ortiz O; Costello R; Cadena J; Diaz C; Gulley JL; Dahut WL; Streicher H; Wright JJ; Trepel JB; Bottaro DP; Apolo AB
Clin Cancer Res; 2021 Mar; 27(5):1391-1398. PubMed ID: 33262136
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
[TBL] [Abstract][Full Text] [Related]
11. Post-therapeutic circulating tumor cell-associated white blood cell clusters predict poor survival in patients with advanced driver gene-negative non-small cell lung cancer.
Wang Y; Liu Y; Zhang Z; Lu B; Gao Y; Tong L; Hu M; Lin PP; Li B; Zhang T
BMC Cancer; 2023 Jun; 23(1):578. PubMed ID: 37349714
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to Progression.
Cappelletti V; Verzoni E; Ratta R; Vismara M; Silvestri M; Montone R; Miodini P; Reduzzi C; Claps M; Sepe P; Daidone MG; Procopio G
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098246
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
Lorente D; Olmos D; Mateo J; Dolling D; Bianchini D; Seed G; Flohr P; Crespo M; Figueiredo I; Miranda S; Scher HI; Terstappen LWMM; de Bono JS
Ann Oncol; 2018 Jul; 29(7):1554-1560. PubMed ID: 29741566
[TBL] [Abstract][Full Text] [Related]
14. Perioperative Circulating Tumor Cells (CTCs), MCTCs, and CTC-White Blood Cells Detected by a Size-Based Platform Predict Prognosis in Renal Cell Carcinoma.
Wang Z; Zhang P; Chong Y; Xue Y; Yang X; Li H; Wang L; Zhang Y; Chen Q; Li Z; Xue L; Li H; Chong T
Dis Markers; 2021; 2021():9956142. PubMed ID: 34733376
[TBL] [Abstract][Full Text] [Related]
15. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
16. Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer.
Sinoquet L; Jacot W; Gauthier L; Pouderoux S; Viala M; Cayrefourcq L; Quantin X; Alix-Panabières C
Clin Chem; 2021 Nov; 67(11):1503-1512. PubMed ID: 34355741
[TBL] [Abstract][Full Text] [Related]
17. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
[TBL] [Abstract][Full Text] [Related]
18. Dynamic changes of different phenotypic and genetic circulating tumor cells as a biomarker for evaluating the prognosis of RCC.
Wang ZL; Zhang P; Li HC; Yang XJ; Zhang YP; Li ZL; Xue L; Xue YQ; Li HL; Chen Q; Chong T
Cancer Biol Ther; 2019; 20(4):505-512. PubMed ID: 30359544
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.
Giuliano M; Giordano A; Jackson S; Hess KR; De Giorgi U; Mego M; Handy BC; Ueno NT; Alvarez RH; De Laurentiis M; De Placido S; Valero V; Hortobagyi GN; Reuben JM; Cristofanilli M
Breast Cancer Res; 2011 Jun; 13(3):R67. PubMed ID: 21699723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
